Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
Joachim AlexandreJoe-Elie SalemJavid MoslehiMarion SassierCamille RopertJennifer CautelaFranck ThunyStéphane EderhyAriel CohenGhandi DamajJean-Pierre VilqueAnne-Flore PlaneDamien LegalloisLaure Champ-RigotPaul MilliezChristian Funck-BrentanoCharles DolladillePublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Although cancer malignancy itself may generate AF, we identified 19 anticancer drugs significantly associated with a significant increase in AF over-reporting. This pharmacovigilance study provides evidence that anticancer drugs themselves could represent independent risk factors for AF development. Dedicated prospective clinical trials are now required to confirm these 19 associations. This list of suspected anticancer drugs should be known by physicians when confronted to AF in cancer patients, particularly in case of haematologic malignancies.
Keyphrases
- atrial fibrillation
- adverse drug
- clinical trial
- drug induced
- oral anticoagulants
- left atrial
- catheter ablation
- direct oral anticoagulants
- left atrial appendage
- heart failure
- randomized controlled trial
- papillary thyroid
- squamous cell carcinoma
- emergency department
- coronary artery disease
- squamous cell
- phase ii
- electronic health record
- phase iii